Engineering of bacterial strains and their products for cancer therapy

Bernardes, Nuno; Chakrabarty, Ananda M.; Fialho, Arsénio M.

doi:10.1007/s00253-013-4926-6

Cited by 61 publications

(42 citation statements)

References 72 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pseudomonas syringae do inject detrimental effectors; Lindeberg et al ., ). Also, shocking as it may look in first sight, P. aeruginosa infections have even been suggested to have a role in defending the human host against cancer (Bernardes et al ., ; Chakrabarty, ). Can we then make a clear division between good and bad bacteria only on the basis of their taxonomic ID and the recognizable determinants encoded in their genome?…”

mentioning

confidence: 99%

Pseudomonas aeruginosa: the making of a pathogen

Lorenzo

2014

Environmental Microbiology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Pseudomonas aeruginosa: the making of a pathogen

Lorenzo

2014

Environmental Microbiology

View full text Add to dashboard Cite

“…RITs are expressed mainly using yeast, bacteria, or cell expression systems [54, 55]. Each system has its unique features, but, as an expression system, two critical requirements must be met: (1) capability of properly folding complex proteins with multiple domains and (2) resistance to the toxin moiety.…”

Section: Smart Design and Expression Of Ritsmentioning

confidence: 99%

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

Zhu

Liu

Wang

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Recombinant immunotoxins (RITs) refer to a group of recombinant protein-based therapeutics, which consists of two components: an antibody variable fragment or a specific ligand that allows RITs to bind specifically to target cells and an engineered toxin fragment that kills the target cells upon internalization. To date, over 1,000 RITs have been generated and significant success has been achieved in the therapy of hematological malignancies. However, the immunogenicity and off-target toxicities of RITs remain as significant barriers for their application to solid tumor therapy. A group of RITs have also been generated for the treatment of glioblastoma multiforme, and some have demonstrated evidence of tumor response and an acceptable profile of toxicity and safety in early clinical trials. Different from other solid tumors, how to efficiently deliver the RITs to intracranial tumors is more critical and needs to be solved urgently. In this article, we first review the design and expression of RITs, then summarize the key findings in the preclinical and clinical development of RIT therapy of glioblastoma multiforme, and lastly discuss the specific issues that still remain to forward RIT therapy to clinical practice.

show abstract

“…Bacterial proteins have been extensively studied as anticancer agents [2]. These proteins found to act on tumor cells specifically and cause tumor regression through growth inhibition; cell cycle arrest and apoptosis induction [3]. Protein from Pseudomonas aeruginosa, Streptococcus pneumoniae, Corynebacterium diphtheria and enterococcus sp.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Different Culture Media for Enhanced Production of Pseudomonas Aeruginosa (Mtcc No 2453) Biomass and Its Proteins

Neeraja

Tigulla

Sudhakar

2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Microorganisms, especially bacteria and its proteins have proven to be potential anti-cancer agents as they selectively attack the tumor cells or tumor micro-environments. The extract of Pseudomonas aeruginosa found to contain proteins that have shown promising anticancer activity. In this work, it was attempted to increase the biomass and trigger the total protein fraction of Pseudomonas aeruginosa (MTCC 2453). Methods:The organism was cultivated in three different such as Luria-Bertani (LB) broth, minimal medium9 (M9), super broth medium (SB) and asparagine-proline (AP) broth. Asparagine proline broth was selected as it has shown high cell growth rate. The media was further optimized by the addition of NaHCO3 and copper sulphate to trigger the protein production. Optimized Aspergine proline broth has achieved highest cell biomass. After the shake flask culture, the overnight grown culture in optimized AP medium was further grown in a 5 L bioreactor by fed-batch cultivation to achieve higher cell densities. Results:The highest protein production was achieved at 40 ° C. Highest biomass and protein content was observed at pH 8 while lowest biomass was produced at pH 2. A gradual increase in biomass content observed from 12 h towards to 48 h. Conclusion:High biomass and proteins content and of Pseudomonas aeruginosa (MTCC 2453) can be produced in optimized asparagine-proline broth. Further the extract is purified to produce novel anti-cancer proteins.

show abstract

Engineering of bacterial strains and their products for cancer therapy

Cited by 61 publications

References 72 publications

Pseudomonas aeruginosa: the making of a pathogen

Pseudomonas aeruginosa: the making of a pathogen

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

Evaluation of Different Culture Media for Enhanced Production of Pseudomonas Aeruginosa (Mtcc No 2453) Biomass and Its Proteins

Contact Info

Product

Resources

About